本次申请银行综合授信额度尚需提交公司股东大会审议。 特此公告。 上海海顺新型药用包装材料股份有限公司 | 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-041 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 关于申请2024年度综合授信额度的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年4月17日召开了第五届董事会第十八次会议和第五届监事会 第十六次会议，审议通过了《关于申请2024年度综合授信额度的议案》， 同意公司及子公司向银行申请不超过人民币18亿元的综合授信额度， 以满足公司日常生产经营和业务发展的资金需求，授信期限为本年度 股东大会审议批准之日起至下一年度股东大会召开之日有效。 综合授信内容包括但不限于流动资金贷款、信用证、银行承兑汇 票、保函、应收账款贸易融资、超短融票据授信、建设项目贷款、并 购贷款等业务（具体授信银行、 ...

上海海顺新型药用包装材料股份有限公司 第五届董事会独立董事专门会议2024年第三次会议决议 一、独立董事专门会议召开情况 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 （二）审议通过《关于续聘公司2024年度审计机构的议案》 天健会计师事务所（特殊普通合伙）执业经验丰富，具备承担公 司年度财务审计和其他审计的工作能力，在从事公司审计工作中尽职 尽责，能按照中国注册会计师审计准则的要求从事公司会计报表审计 工作，能遵守会计师事务所的职业道德规范，客观、公正的对公司会 计报表发表意见。公司本次续聘天健会计师事务所（特殊普通合伙） 为公司 2024 年度审计机构，相关决策程序符合相关法律、法规和《公 司章程》的规定，不存在损害公司及中小股东利益的情形。我们一致 同意该议案，并同意提交公司董事会会议审议。 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会独立董事专门会议 2024 年第三次会议（以下简称"独 立董事专门会议"）于 2024 年 4 月 15 日以现场会议的方式召开，本 次会议应出席独立董事 3 人，实际出席 ...

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-044 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 特此公告。 上海海顺新型药用包装材料股份有限公司 关于举办2023年度业绩说明会的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 公司定于2024年4月25日（星期四）15：00-17：00在全景网举行 2023年度业绩说明会。本次业绩说明会将会采用网络远程的方式举行， 投资者可登录"全景网投资者关系互动平台"（http://ir.p5w.net） 参与本次业绩说明会。 net/zj/,进入问题征集专题页面。公司将在2023年度业绩说明会上， 对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年4月17日在巨潮资讯网（http://www.cninfo.com.cn）披露 了2023年年度报告及年度报告摘要。为了更好地与广大投资者进行交 流，使投资 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,020,872,006.74, representing a 0.82% increase compared to CNY 1,012,601,235.55 in 2022[21]. - Net profit attributable to shareholders decreased by 16.61% to CNY 85,441,741.28 in 2023 from CNY 102,461,491.00 in 2022[21]. - The net profit after deducting non-recurring gains and losses was CNY 68,444,591.61, down 26.91% from CNY 93,649,802.79 in the previous year[21]. - The net cash flow from operating activities was CNY 100,596,592.11, a decrease of 26.55% compared to CNY 136,957,656.04 in 2022[21]. - Total assets increased by 29.55% to CNY 2,986,593,236.85 at the end of 2023, up from CNY 2,305,352,111.13 at the end of 2022[21]. - The company's net assets attributable to shareholders rose by 14.68% to CNY 1,831,064,236.93 at the end of 2023, compared to CNY 1,596,620,328.83 at the end of 2022[21]. - The basic earnings per share decreased by 16.98% to CNY 0.44 in 2023 from CNY 0.53 in 2022[21]. - The company achieved a total revenue of ¥1,020,872,006.74 in 2023, representing a year-on-year growth of 0.82%[52]. - Net profit attributable to shareholders decreased by 16.61% to ¥85,441,741.28, primarily due to increased financing costs and expanded production capacity[52]. - Revenue from new pharmaceutical packaging materials accounted for 91.79% of total revenue, with a year-on-year increase of 2.75%[57]. - Domestic sales contributed 89.06% of total revenue, with a slight increase of 0.09% compared to the previous year[57]. - The company reported a total sales volume of 33,408,530.94 kg, which is a 0.86% increase from the previous year[59]. - The company reported a total revenue of 1,007 million in the latest financial year[138]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[196]. Market and Industry Trends - The pharmaceutical packaging materials industry in China has surpassed a market size of 100 billion yuan, reflecting stable growth in market demand[32]. - The company focuses on high-barrier, low-adsorption, and anti-corrosion packaging materials, aiming to provide professional and precise packaging solutions for clients[36]. - The government has introduced a series of regulations to enhance the quality control standards for pharmaceutical packaging materials, requiring companies to meet higher quality thresholds[34]. - The introduction of smart packaging and anti-counterfeiting technologies is encouraged to promote industry innovation and upgrade[35]. - The government is guiding the pharmaceutical packaging industry towards consolidation and cluster development to increase industry concentration[35]. - The company is actively exploring packaging solutions in new consumption and new energy sectors, developing a series of innovative packaging materials[42]. - The company aims to enhance its export business, with a target of increasing export sales by 99.48% in the next fiscal year[107]. - The company plans to expand its market presence by launching new products, including advanced PVC and PVDC composite materials, targeting a 30% increase in production capacity by 2024[108]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[196]. Research and Development - The company has successfully applied for and obtained 152 patents, including 21 invention patents and 126 utility model patents, covering key areas such as basic material research and production process improvements[48]. - Research and development expenses increased by 13.17% to ¥50,351,367.93, indicating a focus on innovation and product development[66]. - The company is developing a new type of high-temperature sterilization liquid packaging composite film, which has completed preliminary feasibility studies and is currently in the small batch trial production stage[67]. - The company is also working on a new anti-counterfeiting PTP aluminum foil, which has completed feasibility studies and is in the customer feedback stage for small batch production[68]. - The company is committed to independent research and development, ensuring that new products meet stringent industry standards[69]. - The company is focusing on enhancing the performance of its packaging materials to ensure they meet various application environments[69]. - The company is committed to advancing its R&D efforts to align with international sustainability initiatives and market trends[70]. - The company plans to invest 100 million yuan in R&D for new technologies aimed at enhancing product efficiency[148]. Corporate Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operation from its controlling shareholders[131]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[131]. - The company emphasizes transparency in information disclosure, utilizing multiple platforms to ensure equal access for all shareholders[133]. - The company has conducted online investor communication sessions on April 7, 2023, and August 29, 2023, discussing business development and strategic direction[133]. - The company has established specialized committees within the board to provide scientific and professional advice for decision-making[132]. - The company has implemented a "Quality Return Dual Improvement" action plan, although details on its execution were not disclosed[129]. - The management team includes experienced professionals with backgrounds in finance and materials, such as Lin Wuhui, who is the chairman and general manager[139]. - The management emphasized the importance of sustainability in new strategies, aiming for a 30% reduction in carbon footprint by 2025[148]. Environmental Responsibility - The company adheres to multiple environmental protection laws, including the Air Pollution Prevention Law and the Water Pollution Prevention Law, ensuring compliance in its operations[182]. - The company has implemented effective measures to prevent and control environmental risks in accordance with relevant laws and regulations[188]. - The company has invested in waste gas treatment equipment and continuous monitoring systems to ensure compliance with environmental laws[188]. - The company is committed to environmental responsibility, following strict regulations and maintaining a high standard of operational compliance[182]. - The company focuses on producing high-performance, low-carbon, and environmentally friendly packaging materials, such as recyclable composite materials[190]. - The company has committed to reducing carbon emissions by 25% by 2025 as part of its sustainability strategy[196]. Employee and Talent Management - The company has established a performance-based salary system, adjusting employee compensation annually based on company performance and individual contributions[166]. - The company has implemented a comprehensive welfare system, including social insurance and various employee benefits, to retain talent[166]. - The company emphasizes training programs for new employees and marketing personnel to enhance skills and knowledge[167]. - The total number of employees at the end of the reporting period is 896, with 24 in the parent company and 343 in major subsidiaries[164]. - The professional composition includes 555 production personnel, 98 sales personnel, 125 technical personnel, 29 financial personnel, and 89 administrative personnel[165]. - The educational background of employees shows 19 with master's degrees or above, 152 with bachelor's degrees, 186 with associate degrees, and 539 with high school or lower education[165]. Strategic Initiatives - The company plans to continue expanding its market presence and developing new products, although specific details on future strategies were not disclosed in the report[31]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals[148]. - The company aims to enhance its R&D efforts in high-barrier packaging materials, focusing on pharmaceutical, medical, new consumption, and new energy sectors, with a commitment to developing recyclable composite materials and functional polyolefin film materials[119]. - The company will deepen cooperation with upstream and downstream enterprises in the industry chain to optimize supply chain management, improve raw material supply stability, and reduce production costs[116].

关于上海海顺新型药用包装材料股份有限公司 2023 年度募集资金存放与使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为上海海顺 新型药用包装材料股份有限公司（以下简称"海顺新材"、"上市公司"或"公司"） 向特定对象发行股票与向不特定对象发行可转换公司债券的保荐机构，根据《证 券发行上市保荐业务管理办法》等有关规定，对海顺新材 2023 年度募集资金存 放与使用情况进行了核查，核查情况如下： 一、募集资金基本情况 （一）2021 年向特定对象发行股票 1、实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意上海海顺新型药用包装材料股份有 限公司向特定对象发行股票注册的批复》（证监许可〔2021〕2377 号），公司 由主承销商中信证券股份有限公司采用询价方式，向特定对象发行人民币普通股 （A 股）股票 37,181,705 股，发行价为每股人民币 16.18 元，共计募集资金 601,599,986.90 元，坐扣承销和保荐费用 3,309,433.90 元（不含税）以及税金 198,566.03 元后的募集资金为 598,091,986.97 元，已由主承销 ...

一、召开会议基本情况 1、股东大会届次：2023年年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法性及合规性： 关于召开2023年年度股东大会的通知 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | | 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-043 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年4月17日召开了第五届董事会第十八次会议，会议决定于 2024年5月8日（星期三）召开公司2023年年度股东大会。本次股东大 会采用现场投票、网络投票相结合的方式进行，现发布关于召开公司 2023年年度股东大会通知如下： 公司于2024年4月17日召开的第五届董事会第十八次会议，审议 通过《关于召开2023年年度股东大会的议案》。本次股东大会的召集 程序符合《公司法》《上市公司股东大会规则》等法律、规范性文件 及《公司章程》的相 ...

上海海顺新型药用包装材料股份有限公司 董事会对独立董事独立性的专项评估意见 上海海顺新型药用包装材料股份有限公司 董事会 2024年4月17日 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》等要求，上海海顺新型药用包装材料股份有 限公司（以下简称"公司"）董事会，就公司2023年任独立董事夏宽 云、马石泓、王琳琳的独立性情况进行评估并出具如下专项意见： 经核查2023年度在任的独立董事夏宽云、马石泓、王琳琳的任职 经历以及签署的相关自查文件，上述人员未在公司担任除独立董事以 外的任何职务，也未在公司主要股东公司担任任何职务，与公司以及 主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断 的关系，因此，公司独立董事符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》中对独立董事独立性的相关要求。 ...

上海海顺新型药用包装材料股份有限公司 2024年董事、监事及高级管理人员薪酬方案 2、监事的薪酬 为促进上海海顺新型药用包装材料股份有限公司（以下简称"公 司"）健康、可持续发展，增强公司董事、监事及高级管理人员勤勉 尽责、忠实诚信的工作意识，充分调动其积极性、创造性，提升管理 水平，有效提升公司的整体绩效，从而促进公司实现经营目标，保持 企业健康、规范、可持续发展，根据《公司章程》、《薪酬与考核委 员会议事规则》，同时参考国内同行业上市公司非独立董事、监事及 高级管理人员的薪酬水平，结合公司的实际运营情况，经董事会薪酬 与考核委员会提议，制定了公司2024年董事、监事及高级管理人员薪 酬方案。 一、适用对象 在公司领取薪酬的董事、监事、高级管理人员。 二、本议案适用期限 2024年1月1日至2024年12月31日。 三、发放薪酬标准 1、公司董事的薪酬 公司独立董事在公司领取独立董事津贴，津贴标准为每年 6 万元 （税前）；其他董事根据其在公司担任的具体职务，按公司相关薪酬 与绩效考核管理制度领取薪酬，不再另行领取津贴。 2024 年 4 月 17 日 公司监事根据其在公司担任的具体职务，按公司相关薪酬与绩 ...

上海海顺新型药用包装材料股份有限公司 三、财务报表附注…………………………………………………第 14—96 页 四、附件………………………………………………………… 第 97—100 页 （一）本所营业执照复印件…………………………………… 第 97 页 （二）本所执业证书复印件…………………………………… 第 98 页 （三）本所签字注册会计师执业证书复印件…………… 第 99—100 页 审 计 报 告 2023 年度审计报告 天健会计师事务 所 Pan-China Certified Public Accountants | | | | 一、审计报告……………………………………………………… 第 1—5 | | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 6—13 | | 页 | | （一）合并资产负债表…………………………………………… 第 | 6 | 页 | | （二）母公司资产负债表………………………………………… 第 | 7 | 页 | | （三）合并利润表………………………………………………… 第 | 8 | 页 | | （四 ...

上海海顺新型药用包装材料股份有限公司 关于募集资金年度存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求（2022 年修订）》（证监会 公告〔2022〕15 号）和深圳证券交易所印发的《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作（2023 年 12 月修订）》（深证上〔2023〕1146 号）的规定，将本公司募集资 金 2023 年度存放与使用情况专项说明如下。 一、募集资金基本情况 (一) 2021 年向特定对象发行股票 1. 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2021〕2377 号文核准， 并经深圳证券交易所同意，本公司由主承销商中信证券股份有限公司 采用询价方式，向特定对象发行人民币普通股（A 股）股票 37,181,705 股，发行价为每股人民币 16.18 元，共计募集资金 601,599,986.90 元，坐扣承销和保荐费用 3,309,433.90 元（不含税）以及税金 198,566.03 元后的募集资金为 598,091,986.97 元，已由主承销商中 信证 ...